➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Dow
Johnson and Johnson
Merck
Moodys

Last Updated: December 5, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DULOXETINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Duloxetine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00036309 Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder Completed Eli Lilly and Company Phase 3 2002-05-01 The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.
NCT00036335 Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain Completed Eli Lilly and Company Phase 3 2002-03-01 The purposes of this study are to determine whether an investigational drug can help patients suffering from major depression with pain symptoms, and gather data on the safety of the investigational drug including any side effects that might be associated with it.
NCT00042562 Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression Completed Eli Lilly and Company Phase 3 2002-12-01 The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression. The safety associated with switching from a medication you may be taking for depression to taking duloxetine. It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate duloxetine for other possible uses or for other medical or scientific purposes other than those currently proposed.
NCT00042575 Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression Completed Eli Lilly and Company Phase 3 2002-06-01 The Purposes of this Study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression. It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate duloxetine for other possible uses or for other medical or scientific purposes other than those currently proposed. Duloxetine might not have any good effects for you.
NCT00058968 A Study for the Treatment of Painful Diabetic Neuropathy Completed Eli Lilly and Company Phase 3 2002-10-01 The purpose of the study is to determine if duloxetine can help patients with painful diabetic neuropathy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Duloxetine Hydrochloride

Condition Name

Condition Name for Duloxetine Hydrochloride
Intervention Trials
Major Depressive Disorder 53
Depression 30
Fibromyalgia 19
Pain 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Duloxetine Hydrochloride
Intervention Trials
Depression 110
Depressive Disorder 106
Depressive Disorder, Major 77
Disease 54
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Duloxetine Hydrochloride

Trials by Country

Trials by Country for Duloxetine Hydrochloride
Location Trials
United States 974
Canada 60
United Kingdom 32
France 30
Australia 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Duloxetine Hydrochloride
Location Trials
New York 53
California 51
Florida 50
Texas 47
Ohio 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Duloxetine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Duloxetine Hydrochloride
Clinical Trial Phase Trials
Phase 4 100
Phase 3 93
Phase 2/Phase 3 8
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Duloxetine Hydrochloride
Clinical Trial Phase Trials
Completed 184
Recruiting 42
Not yet recruiting 32
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Duloxetine Hydrochloride

Sponsor Name

Sponsor Name for Duloxetine Hydrochloride
Sponsor Trials
Eli Lilly and Company 127
Boehringer Ingelheim 38
Shionogi 10
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Duloxetine Hydrochloride
Sponsor Trials
Industry 224
Other 220
NIH 21
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Baxter
Mallinckrodt
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.